<DOC>
	<DOCNO>NCT00895882</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy vaniprevir administer concomitantly pegylated interferon ( peg-IFN ) ribavirin ( RBV ) treat treatment-naive genotype 1 hepatitis C virus ( HCV ) -infected patient .</brief_summary>
	<brief_title>Study Evaluate Different Regimens Vaniprevir ( MK7009 ) Treatment Chronic Genotype 1 Hepatitis C Virus Infection Treatment-naive Patients ( MK-7009-019 ) ( WITHDRAWN )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patient chronic genotype 1 HCV infection Patient liver biopsy without evidence cirrhosis Patient eye exam prior start study Female patient capable child male patient female partner capable child agree use two form birth control throughout study Patient previous treatment : 3 dos IFN , pegIFN , and/or RBV ; stop treatment due intolerance one drug ; antiviral investigational therapy vaccine HCV Female patient pregnant breastfeeding Patient chronic hepatitis cause HCV Patient evidence cirrhosis liver Patient HIV Patient active hepatitis B infection Patient nongenotype 1 HCV infection Patient consume excessive amount alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>